Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Targeted therapy

KRAS degradation averts PDAC chemoresistance

Nature Cancer volume 5, pages 375–377 (2024)Cite this article

Subjects

Effectively targeting deregulated KRAS signaling remains an unmet clinical need, as current approaches commonly lead to the development of chemoresistance in clinical settings. ADAM9-mediated lysosomal KRAS degradation is now shown to counteract PDAC chemoresistance independently of mutational status.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Targeting KRAS signaling in PDAC.

References

  1. Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. CA Cancer J. Clin. 73, 17–48 (2023).

    Article  PubMed  Google Scholar 

  2. Waters, A. M. & Der, C. J. Cold Spring Harb. Perspect. Med. 8, a031435 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Punekar, S. R., Velcheti, V., Neel, B. G. & Wong, K.-K. Nat. Rev. Clin. Oncol. 19, 637–655 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Huang, Y.-K. et al. Nat. Cancer https://doi.org/10.1038/s43018-023-00720-x (2024).

    Article  PubMed  Google Scholar 

  5. Skoulidis, F. et al. New Engl. J. Med. 384, 2371–2381 (2021).

    Article  CAS  PubMed  Google Scholar 

  6. Jänne, P. A. et al. New Engl. J. Med. 387, 120–131 (2022).

    Article  PubMed  Google Scholar 

  7. Zhao, Y. et al. Nature 599, 679–683 (2021).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  8. Awad, M. M. et al. New Engl. J. Med. 384, 2382–2393 (2021).

    Article  CAS  PubMed  Google Scholar 

  9. Bond, M. J., Chu, L., Nalawansha, D. A., Li, K. & Crews, C. M. ACS Cent. Sci. 6, 1367–1375 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Miyamoto-Sato, E. et al. Molecules 28, 5600 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Shin, W. et al. Exp. Mol. Med. 50, 1–10 (2018).

    PubMed  PubMed Central  Google Scholar 

  12. Yamamoto, K. et al. J. Gastroenterol. 57, 603–618 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hosein, A. N., Dougan, S. K., Aguirre, A. J. & Maitra, A. Nat. Cancer 3, 272–286 (2022).

    Article  PubMed  Google Scholar 

  14. Rojas, L. A. et al. Nature 618, 144–150 (2023).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  15. Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G. & Galluzzi, L. Cancer Cell 39, 310–345 (2021).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. TUM School of Medicine and Health, Technical University Munich, Munich, Germany

    Laura Leonhardt & Matthias Hebrok

  2. Center for Organoid Systems, Technical University Munich, Garching, Germany

    Laura Leonhardt & Matthias Hebrok

  3. Institute for Diabetes and Organoid Technology, Helmholtz Diabetes Center, Helmholtz Zentrum München, Neuherberg, Germany

    Laura Leonhardt & Matthias Hebrok

  4. Munich Institute of Biomedical Engineering (MIBE), Technical University Munich, Munich, Germany

    Matthias Hebrok

  5. German Center for Diabetes Research (DZD), Neuherberg, Germany

    Matthias Hebrok

  6. Diabetes Center, Department of Medicine, University of California San Francisco, San Francisco, CA, USA

    Matthias Hebrok

Authors
  1. Laura Leonhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthias Hebrok
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthias Hebrok.

Ethics declarations

Competing interests

M.H. holds stocks in Encellin Inc. and Thymmune Therapeutics Inc., consults for CV Next and holds stocks in the company, and is the co-founder of Minutia Inc. and holds stocks and options in the company. L.L. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leonhardt, L., Hebrok, M. KRAS degradation averts PDAC chemoresistance. Nat Cancer 5, 375–377 (2024). https://doi.org/10.1038/s43018-023-00708-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-023-00708-7

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing